ZNF629
gene geneOn this page
Also known as KIAA0326
Summary
ZNF629 (zinc finger protein 629, HGNC:29008) is a protein-coding gene on chromosome 16p11.2, encoding Zinc finger protein 629 (Q9UEG4). May be involved in transcriptional regulation.
Predicted to enable DNA binding activity and zinc ion binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.
Source: NCBI Gene 23361 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 105 total
- MANE Select transcript:
NM_001080417
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:29008 |
| Approved symbol | ZNF629 |
| Name | zinc finger protein 629 |
| Location | 16p11.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | KIAA0326 |
| Ensembl gene | ENSG00000102870 |
| Ensembl biotype | protein_coding |
| OMIM | 619587 |
| Entrez | 23361 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000262525, ENST00000896341
RefSeq mRNA: 2 — MANE Select: NM_001080417
NM_001080417, NM_001345970
CCDS: CCDS45463
Canonical transcript exons
ENST00000262525 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000682597 | 30778456 | 30784254 |
| ENSE00000682598 | 30784410 | 30784515 |
| ENSE00000682606 | 30787028 | 30787205 |
Expression profiles
Bgee: expression breadth ubiquitous, 278 present calls, max score 92.10.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.1289 / max 73.4863, expressed in 1743 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 157092 | 13.7652 | 1743 |
| 157091 | 0.3637 | 179 |
Top tissues by expression
295 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| type B pancreatic cell | CL:0000169 | 92.10 | gold quality |
| olfactory bulb | UBERON:0002264 | 91.97 | gold quality |
| diaphragm | UBERON:0001103 | 89.77 | silver quality |
| tendon of biceps brachii | UBERON:0008188 | 87.40 | gold quality |
| apex of heart | UBERON:0002098 | 85.58 | gold quality |
| endometrium epithelium | UBERON:0004811 | 85.16 | gold quality |
| paraflocculus | UBERON:0005351 | 84.52 | gold quality |
| nasal cavity epithelium | UBERON:0005384 | 84.47 | gold quality |
| cortical plate | UBERON:0005343 | 83.96 | gold quality |
| tibialis anterior | UBERON:0001385 | 83.53 | silver quality |
| left ventricle myocardium | UBERON:0006566 | 83.48 | silver quality |
| endothelial cell | CL:0000115 | 83.39 | silver quality |
| ganglionic eminence | UBERON:0004023 | 82.73 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 82.65 | gold quality |
| heart left ventricle | UBERON:0002084 | 82.61 | gold quality |
| cardiac ventricle | UBERON:0002082 | 82.56 | gold quality |
| heart right ventricle | UBERON:0002080 | 82.45 | gold quality |
| middle frontal gyrus | UBERON:0002702 | 82.41 | gold quality |
| cardiac muscle of right atrium | UBERON:0003379 | 82.30 | gold quality |
| ventricular zone | UBERON:0003053 | 82.26 | gold quality |
| inferior olivary complex | UBERON:0002127 | 81.99 | gold quality |
| frontal pole | UBERON:0002795 | 81.94 | gold quality |
| embryo | UBERON:0000922 | 81.57 | gold quality |
| stromal cell of endometrium | CL:0002255 | 81.44 | gold quality |
| medial globus pallidus | UBERON:0002477 | 81.41 | gold quality |
| quadriceps femoris | UBERON:0001377 | 81.36 | silver quality |
| Brodmann (1909) area 10 | UBERON:0013541 | 81.20 | gold quality |
| CA1 field of hippocampus | UBERON:0003881 | 80.85 | silver quality |
| deltoid | UBERON:0001476 | 80.83 | silver quality |
| heart | UBERON:0000948 | 80.63 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-100618 | yes | 258.96 |
| E-ANND-3 | no | 3.09 |
Regulation
Is transcription factor: no
Cross-species orthologs
2 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Zfp629 | ENSMUSG00000045639 |
| rattus_norvegicus | Zfp629 | ENSRNOG00000018877 |
Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631), ZNF3 (ENSG00000166526)
Protein
Protein identifiers
Zinc finger protein 629 — Q9UEG4 (reviewed: Q9UEG4)
Alternative names: Zinc finger protein 65
All UniProt accessions (1): Q9UEG4
UniProt curated annotations — full annotation on UniProt →
Function. May be involved in transcriptional regulation.
Subcellular location. Nucleus.
Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.
RefSeq proteins (2): NP_001073886, NP_001332899 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR013087 | Znf_C2H2_type | Domain |
| IPR036236 | Znf_C2H2_sf | Homologous_superfamily |
| IPR050758 | Znf_C2H2-type | Family |
Pfam: PF00096
UniProt features (34 total): zinc finger region 19, compositionally biased region 4, cross-link 4, region of interest 3, modified residue 2, chain 1, sequence variant 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9UEG4-F1 | 64.33 | 0.13 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (6): 18, 616, 251, 688, 750, 840
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 135 (showing top):
KOYAMA_SEMA3B_TARGETS_UP, chr16p11, HAMAI_APOPTOSIS_VIA_TRAIL_DN, SAFFORD_T_LYMPHOCYTE_ANERGY, SENESE_HDAC3_TARGETS_DN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP, KYNG_WERNER_SYNDROM_AND_NORMAL_AGING_DN, MARTENS_TRETINOIN_RESPONSE_DN, LU_EZH2_TARGETS_UP, KRIEG_HYPOXIA_NOT_VIA_KDM3A, IL2_UP.V1_DN, IL21_UP.V1_DN, DIDO1_TARGET_GENES, FOXD2_TARGET_GENES
GO Biological Process (1): regulation of transcription by RNA polymerase II (GO:0006357)
GO Molecular Function (4): DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)
GO Cellular Component (1): nucleus (GO:0005634)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| regulation of DNA-templated transcription | 1 |
| transcription by RNA polymerase II | 1 |
| nucleic acid binding | 1 |
| transition metal ion binding | 1 |
| binding | 1 |
| cation binding | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
2092 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ZNF629 | TRIM28 | Q13263 | 981 |
| ZNF629 | ZUP1 | Q96AP4 | 856 |
| ZNF629 | USP5 | P45974 | 819 |
| ZNF629 | UBB | P02248 | 811 |
| ZNF629 | YOD1 | Q5VVQ6 | 788 |
| ZNF629 | USP44 | Q9H0E7 | 773 |
| ZNF629 | OTUD7A | Q8TE49 | 740 |
| ZNF629 | SETDB1 | Q15047 | 673 |
| ZNF629 | ZPR1 | O75312 | 670 |
| ZNF629 | CRBN | Q96SW2 | 663 |
| ZNF629 | HDAC6 | Q9UBN7 | 653 |
| ZNF629 | UBA2 | Q9UBT2 | 647 |
| ZNF629 | PHF20 | Q9BVI0 | 638 |
| ZNF629 | NPLOC4 | Q8TAT6 | 568 |
| ZNF629 | ZFAND5 | O76080 | 558 |
IntAct
155 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| YWHAB | PIK3C2A | psi-mi:“MI:0914”(association) | 0.800 |
| GTF3C3 | POLR3D | psi-mi:“MI:0914”(association) | 0.640 |
| YWHAG | BLTP3B | psi-mi:“MI:0914”(association) | 0.640 |
| IPO8 | TRIM28 | psi-mi:“MI:0914”(association) | 0.640 |
| LIN28A | IGF2BP3 | psi-mi:“MI:0914”(association) | 0.640 |
| YWHAE | PIK3C2A | psi-mi:“MI:0914”(association) | 0.570 |
| YWHAH | BLTP3B | psi-mi:“MI:0914”(association) | 0.570 |
| YWHAZ | PIK3C2A | psi-mi:“MI:0914”(association) | 0.570 |
| ZNF629 | YJU2B | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF629 | TEPSIN | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF629 | PPP1CC | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 | |
| CCHCR1 | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CDR2L | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| HNF4G | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF629 | ZRANB1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GOLGA6L9 | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| GAS8 | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| LDOC1 | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TRIM41 | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF438 | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| JRK | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SMARCD1 | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| SPG21 | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF629 | RSPH14 | psi-mi:“MI:0915”(physical association) | 0.560 |
| ZNF629 | ISY1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TEPSIN | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
| YJU2B | ZNF629 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (141): ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Proximity Label-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-MS), ZNF629 (Affinity Capture-RNA)
ESM2 similar proteins: A1YEV9, A1YG26, A1YG48, A1YG60, A2T712, A2T736, A2T7D2, A2T7L7, A6QPT6, B2KFW1, O14771, O14978, O95125, P10073, P17029, P17040, P59923, Q07231, Q15776, Q16587, Q1LZ87, Q3URR7, Q4KLI1, Q4R8H9, Q53GI3, Q5R670, Q5R741, Q5RJ54, Q5VV52, Q63HK3, Q6A085, Q86W11, Q8BGS3, Q8CF60, Q8IWY8, Q8N393, Q8NF99, Q91VW9, Q969J2, Q96GC6
Diamond homologs: B1H2Q6, G5EGB2, O15535, O75290, P17026, P18724, P18741, P18747, P52742, Q15937, Q17895, Q1LZC0, Q3MJ62, Q4R7X8, Q5R4X5, Q6A085, Q7Z3I7, Q8BGV5, Q8TBZ5, Q91VW9, Q969J2, Q9BRR0, Q9ERU2, Q9ERU3, Q9UEG4, Q9Z1D9, Q9Z2K3, P18715, P18719, P18725, P18729, P18731, P18735, P18737, Q3TDE8, Q966L8, P18714, P18718, P18738, P18740
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 128 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Activation of BAD and translocation to mitochondria | 7 | 62.0× | 2e-10 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 7 | 54.7× | 4e-10 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 7 | 54.7× | 4e-10 |
| Activation of BH3-only proteins | 7 | 40.4× | 4e-09 |
| SARS-CoV-1-host interactions | 13 | 26.6× | 3e-13 |
| RHO GTPases activate PKNs | 7 | 25.8× | 1e-07 |
| Intrinsic Pathway for Apoptosis | 7 | 23.8× | 2e-07 |
| SARS-CoV-1 Infection | 13 | 21.6× | 9e-13 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| cytoplasmic translation | 14 | 22.0× | 1e-12 |
| protein targeting | 5 | 15.5× | 2e-03 |
| ribosomal small subunit biogenesis | 8 | 15.4× | 1e-05 |
| translation | 15 | 13.1× | 2e-10 |
| negative regulation of translation | 6 | 10.0× | 3e-03 |
| rRNA processing | 7 | 8.4× | 2e-03 |
| intracellular protein localization | 8 | 7.1× | 2e-03 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
105 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 94 |
| Likely benign | 5 |
| Benign | 2 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
650 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 16:30784255:CT:C | acceptor_loss | 1.0000 |
| 16:30784514:CC:C | acceptor_gain | 1.0000 |
| 16:30784515:CC:C | acceptor_gain | 1.0000 |
| 16:30784516:C:CA | acceptor_loss | 1.0000 |
| 16:30787027:CGG:C | donor_gain | 1.0000 |
| 16:30787027:CGGCT:C | donor_gain | 1.0000 |
| 16:30787080:AAC:A | donor_gain | 1.0000 |
| 16:30787080:AACC:A | donor_gain | 1.0000 |
| 16:30787081:A:C | donor_gain | 1.0000 |
| 16:30784252:CAC:C | acceptor_gain | 0.9900 |
| 16:30784255:C:CC | acceptor_gain | 0.9900 |
| 16:30784404:CCTCA:C | donor_loss | 0.9900 |
| 16:30784405:CTCAC:C | donor_loss | 0.9900 |
| 16:30784406:TCA:T | donor_loss | 0.9900 |
| 16:30784407:CACCT:C | donor_loss | 0.9900 |
| 16:30784408:A:T | donor_loss | 0.9900 |
| 16:30784409:C:CA | donor_loss | 0.9900 |
| 16:30784409:CCT:C | donor_gain | 0.9900 |
| 16:30784511:GGACC:G | acceptor_gain | 0.9900 |
| 16:30784512:GACC:G | acceptor_gain | 0.9900 |
| 16:30784513:ACC:A | acceptor_gain | 0.9900 |
| 16:30784514:CCC:C | acceptor_gain | 0.9900 |
| 16:30784516:C:CC | acceptor_gain | 0.9900 |
| 16:30784516:C:T | acceptor_gain | 0.9900 |
| 16:30787021:AACTC:A | donor_loss | 0.9900 |
| 16:30787022:ACTC:A | donor_loss | 0.9900 |
| 16:30787024:TCA:T | donor_loss | 0.9900 |
| 16:30787025:CA:C | donor_loss | 0.9900 |
| 16:30787026:A:AC | donor_gain | 0.9900 |
| 16:30787026:AC:A | donor_loss | 0.9900 |
AlphaMissense
5757 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 16:30782826:A:G | L501P | 1.000 |
| 16:30782843:G:C | F495L | 1.000 |
| 16:30782843:G:T | F495L | 1.000 |
| 16:30782845:A:G | F495L | 1.000 |
| 16:30782927:G:C | F467L | 1.000 |
| 16:30782927:G:T | F467L | 1.000 |
| 16:30782929:A:G | F467L | 1.000 |
| 16:30782982:T:G | Q449P | 1.000 |
| 16:30782984:G:C | H448Q | 1.000 |
| 16:30782984:G:T | H448Q | 1.000 |
| 16:30782986:G:C | H448D | 1.000 |
| 16:30782986:G:T | H448N | 1.000 |
| 16:30782994:A:G | L445P | 1.000 |
| 16:30783011:G:C | F439L | 1.000 |
| 16:30783011:G:T | F439L | 1.000 |
| 16:30783012:A:G | F439S | 1.000 |
| 16:30783013:A:G | F439L | 1.000 |
| 16:30783034:A:G | C432R | 1.000 |
| 16:30783070:G:C | H420D | 1.000 |
| 16:30783078:A:G | L417P | 1.000 |
| 16:30783095:G:C | F411L | 1.000 |
| 16:30783095:G:T | F411L | 1.000 |
| 16:30783097:A:G | F411L | 1.000 |
| 16:30783118:A:G | C404R | 1.000 |
| 16:30783246:A:G | L361P | 1.000 |
| 16:30783263:G:C | F355L | 1.000 |
| 16:30783263:G:T | F355L | 1.000 |
| 16:30783265:A:G | F355L | 1.000 |
| 16:30783308:G:C | H340Q | 1.000 |
| 16:30783308:G:T | H340Q | 1.000 |
dbSNP variants (sampled 300 via entrez): RS1000152871 (16:30778930 T>A,C), RS1000387459 (16:30786774 G>A,C), RS1000611485 (16:30783891 G>A), RS1001054900 (16:30785957 G>A,C), RS1001081345 (16:30782609 C>A,T), RS1001404331 (16:30785490 C>T), RS1001680733 (16:30787870 A>G), RS1001998718 (16:30784037 C>T), RS1002277226 (16:30786404 G>A), RS1002295598 (16:30778202 C>A,T), RS1002347886 (16:30778551 C>A,G,T), RS1002591817 (16:30786091 A>G), RS1003053732 (16:30786229 C>G,T), RS1003055532 (16:30781436 G>A), RS1003117998 (16:30778534 T>C)
Disease associations
OMIM: gene MIM:619587 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST011956_150 | Systemic lupus erythematosus | 3.000000e-09 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
26 total (human), top 26 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, increases expression | 2 |
| Valproic Acid | decreases expression, increases methylation | 2 |
| Cyclosporine | decreases expression | 2 |
| 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide | decreases expression | 1 |
| GSK-J4 | decreases expression | 1 |
| FR900359 | decreases phosphorylation | 1 |
| TAK-243 | decreases sumoylation | 1 |
| dicrotophos | increases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| perfluorooctanoic acid | decreases expression | 1 |
| benzo(e)pyrene | increases methylation | 1 |
| ferrous chloride | decreases expression | 1 |
| perfluorooctane sulfonic acid | decreases expression | 1 |
| perfluoro-n-nonanoic acid | decreases expression | 1 |
| perfluorohexanesulfonic acid | decreases expression | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| Leflunomide | decreases expression | 1 |
| Enzyme Inhibitors | decreases activity, increases O-linked glycosylation | 1 |
| Lead | affects expression | 1 |
| Methapyrilene | increases methylation | 1 |
| Smoke | decreases expression | 1 |
| Urethane | decreases expression | 1 |
| Zidovudine | affects cotreatment, increases expression | 1 |
| Okadaic Acid | decreases expression | 1 |
| Copper Sulfate | decreases expression | 1 |
| Acrylamide | decreases expression | 1 |
Cellosaurus cell lines
1 cell lines: 1 transformed cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_XW70 | HEK293 eGFP-ZNF629 | Transformed cell line | Female |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.